This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Patient Fitness in AML
The content of this website has been produced in line with the MYLOTARG®▼ (gemtuzumab ozogamicin) Summary of Product Characteristics for Great Britain and Northern Ireland. For MYLOTARG®▼ (gemtuzumab ozogamicin) and cytarabine Prescribing Information Click here. Adverse event reporting information can be found at the bottom of the page.
In this video series, Dr Munisamy covers key topics in the management of de novo AML.
Dr Munisamy discusses the current treatment landscape for de novo AML and shares his experience of treating patients within a District General Hospital (DGH) setting in the UK. He discusses the use of MYLOTARG in patients with de novo AML, highlighting eligibility criteria and considerations for its use.
In video 2, Dr Munisamy focusses on the management of elderly patients with de novo AML. He shares key considerations when selecting treatment, alternative options to intensive chemotherapy, and his experience using MYLOTARG in this patient population.
In video 3, Dr Munisamy covers veno-occlusive disease (VOD) in patients with de novo AML, sharing rationale for VOD surveillance with MYLOTARG treatment and summarising his experience in managing patients at risk of VOD.
In video 4, Dr Munisamy discusses the rationale for fractionated dosing of MYLOTARG in patients with de novo AML and shares his experience of using this treatment – which is both licensed and reimbursed in the UK – in the real-world.
Finally, in video 5, Dr Munisamy discusses the importance of minimal residual disease (MRD) testing in patients with de novo AML, sharing his experience and thoughts on how MRD can be used to optimise clinical outcomes in patients treated with MYLOTARG.
AML, acute myeloid leukaemia; DGH, District General Hospital; MRD, minimal residual disease; VOD, veno-occlusive disease.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024